300396 迪瑞医疗
已收盘 02-24 15:00:00
资讯
新帖
简况
股市必读：迪瑞医疗（300396）2月13日董秘有最新回复
证券之星 · 03:20
股市必读：迪瑞医疗（300396）2月13日董秘有最新回复
迪瑞医疗：截至2026年2月10日，公司股东户数为15,987户
证券之星 · 02-14
迪瑞医疗：截至2026年2月10日，公司股东户数为15,987户
迪瑞医疗上市首亏：华润入主五年仍“叫好不叫座” 亏损逐季扩大业绩全面跑输行业
新浪证券 · 02-13
迪瑞医疗上市首亏：华润入主五年仍“叫好不叫座” 亏损逐季扩大业绩全面跑输行业
迪瑞医疗科技被责令改正，涉订单收入确认不审慎等
蓝鲸财经 · 02-11
迪瑞医疗科技被责令改正，涉订单收入确认不审慎等
股市必读：迪瑞医疗（300396）2月9日董秘有最新回复
中金财经 · 02-10
股市必读：迪瑞医疗（300396）2月9日董秘有最新回复
股市必读：迪瑞医疗因未依法履行其他职责等违规行为被证监会责令改正
证券之星 · 02-09
股市必读：迪瑞医疗因未依法履行其他职责等违规行为被证监会责令改正
迪瑞医疗：纾压蓄力，国际市场继续夯实发展根基
新浪财经 · 02-05
迪瑞医疗：纾压蓄力，国际市场继续夯实发展根基
迪瑞医疗：截至2026年1月31日，公司股东户数为15,812户
证券之星 · 02-05
迪瑞医疗：截至2026年1月31日，公司股东户数为15,812户
迪瑞医疗最新公告：因涉外销售订单收入确认不审慎等问题被吉林证监局责令改正
证券之星 · 02-05
迪瑞医疗最新公告：因涉外销售订单收入确认不审慎等问题被吉林证监局责令改正
迪瑞医疗：上述关联交易是预计和中国华润及其控制企业产生的交易金额
证券之星 · 02-04
迪瑞医疗：上述关联交易是预计和中国华润及其控制企业产生的交易金额
迪瑞医疗：公司产品可覆盖检验科80%以上检测项目
证券之星 · 02-02
迪瑞医疗：公司产品可覆盖检验科80%以上检测项目
股市必读：迪瑞医疗（300396）预计2025年全年扣非后净利润亏损1.85亿元至3.6亿元
证券之星 · 02-02
股市必读：迪瑞医疗（300396）预计2025年全年扣非后净利润亏损1.85亿元至3.6亿元
迪瑞医疗：预计2025年全年归属净利润亏损1.8亿元至3.5亿元
证券之星 · 01-30
迪瑞医疗：预计2025年全年归属净利润亏损1.8亿元至3.5亿元
迪瑞医疗：利用多模态+AI大模型算法技术
证券之星 · 01-29
迪瑞医疗：利用多模态+AI大模型算法技术
迪瑞医疗：印度市场是公司非常重要的境外市场
证券之星 · 01-28
迪瑞医疗：印度市场是公司非常重要的境外市场
迪瑞医疗：截至2026年1月20日，公司股东户数为16,187户
证券之星 · 01-27
迪瑞医疗：截至2026年1月20日，公司股东户数为16,187户
迪瑞医疗：基于多模态+AI大模型算法技术提升诊疗效率
证券之星 · 01-21
迪瑞医疗：基于多模态+AI大模型算法技术提升诊疗效率
股市必读：迪瑞医疗（300396）1月20日董秘有最新回复
证券之星 · 01-21
股市必读：迪瑞医疗（300396）1月20日董秘有最新回复
迪瑞医疗：与北京协和医院开展尿液等领域技术研究
证券之星 · 01-15
迪瑞医疗：与北京协和医院开展尿液等领域技术研究
迪瑞医疗（300396）披露完成工商变更登记，1月14日股价上涨0.07%
证券之星 · 01-14
迪瑞医疗（300396）披露完成工商变更登记，1月14日股价上涨0.07%
暂无数据
公司概况
公司名称：
迪瑞医疗科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2014-09-10
主营业务：
迪瑞医疗科技股份有限公司的主营业务是医疗检验仪器及配套试纸试剂的研发、生产、营销与服务。公司的主要产品是尿液分析、生化分析、化学发光免疫分析、妇科分泌物分析、血细胞分析、凝血分析、整体化实验室七大系列。
发行价格：
29.54
{"stockData":{"symbol":"300396","market":"SZ","secType":"STK","nameCN":"迪瑞医疗","latestPrice":13.44,"timestamp":1771916592000,"preClose":13.15,"halted":0,"volume":5132930,"delay":0,"changeRate":0.0221,"floatShares":272000000,"shares":273000000,"eps":-0.5058,"marketStatus":"已收盘","change":0.29,"latestTime":"02-24 15:00:00","open":13.21,"high":13.7,"low":13.12,"amount":69140100,"amplitude":0.0441,"askPrice":13.44,"askSize":17,"bidPrice":13.43,"bidSize":125,"shortable":0,"etf":0,"ttmEps":-0.5058,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.15,"symbolType":"stock","openAndCloseTimeList":[[1771896600000,1771903800000],[1771909200000,1771916400000]],"highLimit":14.47,"lowLimit":11.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":272700161,"isCdr":false,"pbRate":1.89,"roa":"--","roe":"--","epsLYR":0.52,"committee":-0.045905,"marketValue":3665000000,"turnoverRate":0.0189,"status":0,"floatMarketCap":3660000000},"requestUrl":"/m/hq/s/300396/tweets","defaultTab":"tweets","newsList":[{"id":"2613349627","title":"股市必读：迪瑞医疗（300396）2月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2613349627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613349627?lang=zh_cn&edition=full","pubTime":"2026-02-24 03:20","pubTimestamp":1771874427,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，迪瑞医疗报收于13.15元，下跌0.3%，换手率0.69%，成交量1.88万手，成交额2487.91万元。董秘最新回复投资者： 董秘，销售国外的产品是不是亏损销售的，如果有赚钱的，那里是现在这个业绩，或者是利润造假董秘： 您好投资者，具体经营业绩请您以定期报告为准。投资者： 尊敬的董秘你好，请问截止至2026年2月10日收盘公司股东人数为多少，谢谢！董秘： 截至2026年2月10日，公司股东户数为15,987户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400009868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","300396","BK0028"],"gpt_icon":0},{"id":"2611685119","title":"迪瑞医疗：截至2026年2月10日，公司股东户数为15,987户","url":"https://stock-news.laohu8.com/highlight/detail?id=2611685119","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611685119?lang=zh_cn&edition=full","pubTime":"2026-02-14 16:54","pubTimestamp":1771059247,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)02月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2026年2月10日收盘公司股东人数为多少，谢谢！迪瑞医疗回复：截至2026年2月10日，公司股东户数为15,987户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400013710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0077","300396","BK0028"],"gpt_icon":0},{"id":"2611135911","title":"迪瑞医疗上市首亏：华润入主五年仍“叫好不叫座” 亏损逐季扩大业绩全面跑输行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2611135911","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611135911?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:10","pubTimestamp":1770966600,"startTime":"0","endTime":"0","summary":" 2026年初春，迪瑞医疗遭遇了自2014年登陆科创板以来的最大挑战。作为华润集团耗资18亿元控股的唯一IVD器械上市平台，迪瑞医疗在控股股东入主五年后，不仅未能兑现资源协同的期待，反而暴露出其在日常质量、公司治理等方面的短板。 从迪瑞医疗自身业绩表现看，公司营收、利润表现均跑输行业。 经监管部门核查，迪瑞医疗主要存在两方面问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-02-13/doc-inhmscxc8849540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","BK0077","300396","BK0028"],"gpt_icon":0},{"id":"2610607834","title":"迪瑞医疗科技被责令改正，涉订单收入确认不审慎等","url":"https://stock-news.laohu8.com/highlight/detail?id=2610607834","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610607834?lang=zh_cn&edition=full","pubTime":"2026-02-11 12:48","pubTimestamp":1770785297,"startTime":"0","endTime":"0","summary":"蓝鲸新闻2月11日讯，近日，吉林证监局发布行政监管措施决定书，剑指迪瑞医疗科技股份有限公司及相关责任人。决定书显示，迪瑞医疗科技股份有限公司存在以下问题：一、公司涉外销售订单收入确认不审慎。针对以上问题，吉林证监局决定对迪瑞医疗科技股份有限公司采取责令改正的行政监管措施并记入证券期货市场诚信档案，对王学敏、牛丹丹、张兴艳采取出具警示函的监管措施并记入证券期货市场诚信档案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1770775530162469182","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0028","BK0251","300396","BK0077"],"gpt_icon":0},{"id":"2610608476","title":"股市必读：迪瑞医疗（300396）2月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2610608476","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610608476?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:08","pubTimestamp":1770682087,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年2月9日收盘，迪瑞医疗报收于13.34元，上涨1.37%，换手率0.74%，成交量2.02万手，成交额2688.58万元。投资者： 请问董秘，公司在糖尿病GLP-1，减重药司美格鲁肽，癌症罕见病上的业务能力日益增强，将来是否具备与全球医药巨头相关业务的一争之力，从而更有利的拓展海外市场？ 来自交易信息汇总：2月9日主力资金净流出111.2万元，游资资金净流出248.32万元，散户资金净流入359.52万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260210/32008819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300396","BK0251","BK0077","BK0028"],"gpt_icon":0},{"id":"2610577984","title":"股市必读：迪瑞医疗因未依法履行其他职责等违规行为被证监会责令改正","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577984","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577984?lang=zh_cn&edition=full","pubTime":"2026-02-09 02:02","pubTimestamp":1770573742,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，迪瑞医疗报收于13.16元，下跌0.83%，换手率0.76%，成交量2.07万手，成交额2736.81万元。来自违规处罚提醒：2月5日迪瑞医疗及三位副总经理因信息披露违规被吉林证监局责令改正。违规处罚提醒监管公告2月5日迪瑞医疗公开信息显示，迪瑞医疗科技股份有限公司，副总经理牛丹丹、副总经理张兴艳、王学敏因未依法履行其他职责,信息披露违规被中国证券监督管理委员会吉林监管局责令改正。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900000978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","300396","BK0077"],"gpt_icon":0},{"id":"2609377719","title":"迪瑞医疗：纾压蓄力，国际市场继续夯实发展根基","url":"https://stock-news.laohu8.com/highlight/detail?id=2609377719","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609377719?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:35","pubTimestamp":1770294900,"startTime":"0","endTime":"0","summary":"近日，迪瑞医疗发布2025年度业绩预告。从公告披露内容看，受市场竞争加剧、资产减值等因素影响，公司2025年经营面临阶段性挑战，国内市场业务发展在短期内出现一定波动。公司正多措并举，积极推动国内市场业务企稳向好。 公告显示，2026年迪瑞医疗将重点强化国际市场优势地位，在辐射120多个国家的基础上，确定了“2+2+10”国际战略布局，选取了10个国家作为进一步深度孵育的国家市场，此举将夯实重点市场和提升公司综合竞争能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-05/doc-inhkupsz8762275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","BK0028","300396","BK0077"],"gpt_icon":0},{"id":"2609724693","title":"迪瑞医疗：截至2026年1月31日，公司股东户数为15,812户","url":"https://stock-news.laohu8.com/highlight/detail?id=2609724693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609724693?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:09","pubTimestamp":1770293347,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年1月31日公司的股东数是多少？迪瑞医疗回复：截至2026年1月31日，公司股东户数为15,812户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500036079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","BK0077","300396"],"gpt_icon":0},{"id":"2609374348","title":"迪瑞医疗最新公告：因涉外销售订单收入确认不审慎等问题被吉林证监局责令改正","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374348","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609374348?lang=zh_cn&edition=full","pubTime":"2026-02-05 19:49","pubTimestamp":1770292162,"startTime":"0","endTime":"0","summary":"迪瑞医疗(300396.SZ)公告称，公司收到吉林证监局的行政监管措施决定书，因涉外销售订单收入确认不审慎、涉外销售内部控制不完善等问题，公司被责令改正，王学敏、牛丹丹、张兴艳被出具警示函。涉及2023年多记营业收入369.30万元，占公司2023年营业收入的0.27%。公司及相关人员将进行整改，并加强对相关法律法规的学习。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500035398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300396","BK0251","BK0077","BK0028"],"gpt_icon":0},{"id":"2608359061","title":"迪瑞医疗：上述关联交易是预计和中国华润及其控制企业产生的交易金额","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359061?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:54","pubTimestamp":1770195258,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：华润集团跟迪瑞医疗2026年只交易5千万元，这可以叫做华润协同子公司吗？迪瑞医疗回复：投资者您好！上述关联交易是预计和中国华润及其控制企业产生的交易金额，为初期预判，后续可能根据需求调整，具体信息请以公司披露信息为准，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400028007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","BK0028","300396"],"gpt_icon":0},{"id":"2608851467","title":"迪瑞医疗：公司产品可覆盖检验科80%以上检测项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851467?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:51","pubTimestamp":1770022274,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，印度尼帕病毒爆发，请问公司产品可用于尼帕病毒的相关项目指标监测吗？迪瑞医疗回复：投资者您好！公司产品主要涉及生化、尿液、化学发光、妇科、凝血、血细胞、整体化实验室等，可以覆盖检验科80%以上的检测项目，为预防、治疗疾病提供身体指标参考信息。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0251","300396"],"gpt_icon":0},{"id":"2608588117","title":"股市必读：迪瑞医疗（300396）预计2025年全年扣非后净利润亏损1.85亿元至3.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608588117","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608588117?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:40","pubTimestamp":1769978422,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，迪瑞医疗报收于13.3元，下跌1.48%，换手率1.28%，成交量3.5万手，成交额4661.21万元。迪瑞医疗发布业绩预告，预计2025年全年归属净利润亏损1.8亿元至3.5亿元。关于2026年度日常关联交易预计的公告迪瑞医疗科技股份有限公司于2026年1月30日召开董事会，审议通过《关于2026年日常关联交易预计的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300396"],"gpt_icon":0},{"id":"2607198500","title":"迪瑞医疗：预计2025年全年归属净利润亏损1.8亿元至3.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607198500","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607198500?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:18","pubTimestamp":1769768297,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗发布业绩预告，预计2025年全年归属净利润亏损1.8亿元至3.5亿元。报告期内公司信用减值损失及资产减值损失与上年同期相比有所增长，短期内影响了公司归属于上市公司股东的净利润。报告期内，面对挑战，在控股股东的支持下，公司积极调整经营策略并采取应对措施，优化和调整了管理层，部分举措会在 2026 年全面实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000034104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300396"],"gpt_icon":0},{"id":"2607820300","title":"迪瑞医疗：利用多模态+AI大模型算法技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2607820300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607820300?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:51","pubTimestamp":1769691090,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗01月28日在投资者关系平台上答复投资者关心的问题。感谢您对公司研发创新的关注。具体信息请您以公司定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300396","BK0251","BK0028","BK0077"],"gpt_icon":0},{"id":"2606799536","title":"迪瑞医疗：印度市场是公司非常重要的境外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2606799536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606799536?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:54","pubTimestamp":1769590450,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，迪瑞医疗把印度市场作为重点投入市场是否属实？迪瑞医疗回复：投资者您好！公司海外布局已有20余年，近几年强化本地化管理，在印度设有子公司和本地化团队，是公司非常重要的境外市场，截止目前印度市场公司开始精耕细作阶段，具体信息请以公司定期报告为准，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","MNDmain","BK0077","300396"],"gpt_icon":0},{"id":"2606204822","title":"迪瑞医疗：截至2026年1月20日，公司股东户数为16,187户","url":"https://stock-news.laohu8.com/highlight/detail?id=2606204822","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606204822?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:48","pubTimestamp":1769503704,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)01月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年1月20日，公司股东人数多少？迪瑞医疗回复：截至2026年1月20日，公司股东户数为16,187户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300396","BK0251","BK0077","BK0028"],"gpt_icon":0},{"id":"2605634102","title":"迪瑞医疗：基于多模态+AI大模型算法技术提升诊疗效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2605634102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605634102?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:51","pubTimestamp":1768999898,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗01月20日在投资者关系平台上答复投资者关心的问题。具体信息请以公司定期报告为准，感谢您的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100038907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","300396","BK0028"],"gpt_icon":0},{"id":"2605146889","title":"股市必读：迪瑞医疗（300396）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605146889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605146889?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:35","pubTimestamp":1768937712,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，迪瑞医疗报收于13.51元，下跌0.22%，换手率0.99%，成交量2.69万手，成交额3648.31万元。董秘最新回复投资者： 郭董事长现在要用华润医药商业帮助迪瑞医疗医疗度过难关，你又是华润医药商业法人代表，现在不帮要等何时，郭霆，郎涛有没有能力，见证2025年第四季度业绩一目了然董秘： 投资者您好！投资者： 2025年已经过去了还投票，像2025年那样下去，公司会倒闭的，要2026年重新改头换面，重新开始才是真的董秘： 投资者您好！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100002764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","300396","BK0028"],"gpt_icon":0},{"id":"2603677021","title":"迪瑞医疗：与北京协和医院开展尿液等领域技术研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2603677021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603677021?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:42","pubTimestamp":1768466531,"startTime":"0","endTime":"0","summary":"证券之星消息，迪瑞医疗(300396)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：董事长，总经理，迪瑞跟北京协和医院合作有没有进展，希望回答迪瑞医疗回复：投资者您好！公司与北京协和医院存在科企合作关系，开展尿液等领域的技术研究，相关信息请以定期报告为准。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500026410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","300396","BK0251"],"gpt_icon":0},{"id":"2603612873","title":"迪瑞医疗（300396）披露完成工商变更登记，1月14日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603612873?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:30","pubTimestamp":1768401032,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，迪瑞医疗报收于13.77元，较前一交易日上涨0.07%，最新总市值为37.55亿元。该股当日开盘13.7元，最高14.0元，最低13.55元，成交额达9148.87万元，换手率为2.43%。公司近日发布公告称，迪瑞医疗科技股份有限公司于2025年9月28日和10月24日分别召开第六届董事会第四次临时会议及2025年第二次临时股东大会，审议通过了变更公司经营范围及修订《公司章程》的议案。公司已办理完成工商变更登记手续，并取得新换发的营业执照。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300396","BK0077","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771939910829,"stockEarnings":[{"period":"1week","weight":-0.0008},{"period":"1month","weight":-0.045},{"period":"3month","weight":-0.0713},{"period":"6month","weight":-0.1262},{"period":"1year","weight":-0.1283},{"period":"ytd","weight":0.0194}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪瑞医疗科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"15987人(较上一季度增加1.11%)","perCapita":"17031股","listingDate":"2014-09-10","address":"吉林省长春市朝阳区高新技术产业开发区云河街95号","registeredCapital":"27270万元","survey":" 迪瑞医疗科技股份有限公司的主营业务是医疗检验仪器及配套试纸试剂的研发、生产、营销与服务。公司的主要产品是尿液分析、生化分析、化学发光免疫分析、妇科分泌物分析、血细胞分析、凝血分析、整体化实验室七大系列。","listedPrice":29.54},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪瑞医疗(300396)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪瑞医疗(300396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪瑞医疗,300396,迪瑞医疗股票,迪瑞医疗股票老虎,迪瑞医疗股票老虎国际,迪瑞医疗行情,迪瑞医疗股票行情,迪瑞医疗股价,迪瑞医疗股市,迪瑞医疗股票价格,迪瑞医疗股票交易,迪瑞医疗股票购买,迪瑞医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪瑞医疗(300396)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪瑞医疗(300396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}